Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sotorasib - Amgen

Next Previous
Drug Profile

Sotorasib - Amgen

Alternative Names: AMG-510; LUMAKRAS; LUMYKRAS

Latest Information Update: 11 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen; Carmot Therapeutics
  • Developer Amgen; BeiGene; REVOLUTION Medicines; Verastem Oncology
  • Class Antineoplastics; Piperazines; Pyridines; Pyridones; Pyrimidines; Small molecules
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Colorectal cancer; Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Registered Colorectal cancer
  • Phase III Solid tumours
  • Phase I/II Brain metastases; Pancreatic cancer

Most Recent Events

  • 04 Feb 2025 Preregistration for Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
  • 04 Feb 2025 Registered for Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
  • 07 Aug 2024 Sotorasib receives priority review status for Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top